Vogenx's CEO James Green acquires shares, signaling confidence in the company's future amid a competitive pharmaceutical industry.
| Name | Vogenx, Inc. |
|---|---|
| CIK | 0001903784 |
| Tickers | VOGX |
| Exchanges | Nasdaq |
| Entity type | operating |
| Category | Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company |
| SIC | 2834 Pharmaceutical Preparations |
| EIN | 863697324 |
| LEI | 5299004KM33YCDWS6I69 |
| Fiscal year end | 1231 |
| State of incorporation | DE DE |
| Phone | 9196595677 |
| Website | — |
| Investor website | — |
| Owner org | 03 Life Sciences |
| Flags | — |
| Description | — |
| Insider transactions (issuer) | 1 |
| Insider transactions (owner) | 0 |
EDGAR has no company-logo API. Website field is shown when the filer provided one.
Vogenx's CEO James Green acquires shares, signaling confidence in the company's future amid a competitive pharmaceutical industry.
Vogenx, Inc. Chief Scientific Officer William Wilkison discloses stock transaction in a recent SEC filing, indicating ongoing confidence in the company's growth.
Affinity Asset Advisors, LLC and Michael Cho report a 6.2% stake in Vogenx, Inc., highlighting increased interest in the pharmaceutical sector.
Adage Capital Management has acquired a 5.39% stake in Vogenx, Inc., signaling increased investor interest in the pharmaceutical preparations sector.
Vogenx, Inc. releases quarterly results, focusing on pharmaceutical preparations and ongoing clinical developments. A look at the company's progress and industry impact.
Vogenx, Inc. announces third-quarter financial results and updates on its clinical pipeline, focusing on treatments for metabolic diseases.
Vogenx, Inc. announces Richard Gorman's appointment as Chief Commercial Officer, transitioning from the Board of Directors to strengthen its commercial strategy.
Vogenx, Inc. director Boris Timothy has acquired 50,000 stock options, reflecting the company's strategy to incentivize leadership in the pharmaceutical sector.
Vogenx, Inc. announces stock options granted to CEO James Green, emphasizing commitment to leadership and growth in the pharmaceutical preparations sector.
Vogenx, Inc. grants stock options to CFO Steven R. Delmar, allowing him to purchase 155,000 shares, highlighting management incentives in the pharmaceutical industry.
Vogenx, Inc. grants stock options to Chief Scientific Officer William Wilkison, emphasizing talent retention in the pharmaceutical preparations sector.
45 filing rows loaded from submissions recent.
| Filed | Form | Document | Items | Accession | File no. | Film | Act | Size | XBRL | iXBRL |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | 4 | xslF345X06/ownership.xml | 0001185185-26-005572 | 7785 | ||||||
| 2026-11-20 | 4 | xslF345X06/ownership.xml | 0001185185-26-005570 | 7857 | ||||||
| 2026-11-16 | SCHEDULE 13G | xslSCHEDULE_13G_X02/primary_doc.xml | 0000947871-26-001036 | 005-95922 | 261563360 | 34 | 14871 | |||
| 2026-11-16 | SCHEDULE 13G | xslSCHEDULE_13G_X02/primary_doc.xml | 0001185185-26-005464 | 005-95922 | 261560377 | 34 | 10976 | |||
| 2026-11-16 | SCHEDULE 13G | xslSCHEDULE_13G_X02/primary_doc.xml | 0001185185-26-005463 | 005-95922 | 261560345 | 34 | 12847 | |||
| 2026-11-16 | SCHEDULE 13G | xslSCHEDULE_13G_X02/primary_doc.xml | 0001185185-26-005461 | 005-95922 | 261560260 | 34 | 6484 | |||
| 2026-11-16 | SCHEDULE 13G | xslSCHEDULE_13G_X02/primary_doc.xml | 0001185185-26-005459 | 005-95922 | 261560232 | 34 | 6763 | |||
| 2026-11-13 | SCHEDULE 13G | xslSCHEDULE_13G_X02/primary_doc.xml | 0001011438-26-000688 | 005-95922 | 261552291 | 34 | 17128 | |||
| 2026-11-12 | SCHEDULE 13G | xslSCHEDULE_13G_X02/primary_doc.xml | 0000919574-26-007549 | 005-95922 | 261543868 | 34 | 15519 | |||
| 2026-11-06 | 10-Q | FORM 10-Q | 0001185185-26-005245 | 001-43441 | 261533064 | 34 | 4339602 | 1 | 1 | |
| 2026-11-06 | 8-K | FORM 8-K | 2.02,9.01 | 0001185185-26-005214 | 001-43441 | 261529260 | 34 | 251047 | 1 | 1 |
| 2026-10-09 | 8-K | FORM 8-K | 5.02,7.01,9.01 | 0001185185-26-004679 | 001-43441 | 261452141 | 34 | 215993 | 1 | 1 |
| 2026-10-06 | 4 | xslF345X06/ownership.xml | 0001185185-26-004624 | 5643 | ||||||
| 2026-10-06 | 4 | xslF345X06/ownership.xml | 0001185185-26-004623 | 5648 | ||||||
| 2026-10-06 | 4 | xslF345X06/ownership.xml | 0001185185-26-004622 | 5644 | ||||||
| 2026-10-06 | 4 | xslF345X06/ownership.xml | 0001185185-26-004621 | 5627 | ||||||
| 2026-10-06 | 4 | xslF345X06/ownership.xml | 0001185185-26-004620 | 5599 | ||||||
| 2026-10-06 | 4 | xslF345X06/ownership.xml | 0001185185-26-004619 | 5606 | ||||||
| 2026-09-28 | 3 | xslF345X06/ownership.xml | 0001185185-26-004373 | 15652 | ||||||
| 2026-09-22 | 8-K | FORM 8-K | 5.02,7.01,9.01 | 0001185185-26-004202 | 001-43441 | 261396843 | 34 | 220920 | 1 | 1 |
| 2026-09-17 | 10-Q | FORM 10-Q | 0001185185-26-004101 | 001-43441 | 261387130 | 34 | 3645671 | 1 | 1 | |
| 2026-09-08 | SCHEDULE 13G | xslSCHEDULE_13G_X02/primary_doc.xml | 0001274173-26-000221 | 005-95922 | 261364129 | 34 | 13138 | |||
| 2026-08-19 | 8-K | FORM 8-K | 8.01 | 0001185185-26-003628 | 001-43441 | 261295210 | 34 | 196301 | 1 | 1 |
| 2026-08-13 | 4 | xslF345X06/ownership.xml | 0001185185-26-003507 | 7704 | ||||||
| 2026-08-13 | 4 | xslF345X06/ownership.xml | 0001185185-26-003506 | 7198 | ||||||
| 2026-08-13 | 8-K | FORM 8-K | 5.03,9.01 | 0001185185-26-003505 | 001-43441 | 261274378 | 34 | 479990 | 1 | 1 |
| 2026-08-13 | S-8 | FORM S-8 | 0001185185-26-003503 | 333-298311 | 261274164 | 33 | 225908 | 1 | 1 | |
| 2026-08-12 | 424B4 | FORM 424B4 | 0001185185-26-003448 | 333-297487 | 261267870 | 33 | 4454110 | |||
| 2026-08-11 | EFFECT | xslEFFECTX01/primary_doc.xml | ,, | 9999999995-26-002615 | 333-297487 | 261265151 | 33 | 1737 | ||
| 2026-08-11 | 3 | xslF345X06/ownership.xml | 0001185185-26-003414 | 47432 | ||||||
| 2026-08-11 | 3 | xslF345X06/ownership.xml | 0001185185-26-003413 | 28424 | ||||||
| 2026-08-11 | 3 | xslF345X06/ownership.xml | 0001185185-26-003412 | 7963 | ||||||
| 2026-08-11 | 3 | xslF345X06/ownership.xml | 0001185185-26-003411 | 29395 | ||||||
| 2026-08-11 | 3 | xslF345X06/ownership.xml | 0001185185-26-003410 | 47256 | ||||||
| 2026-08-11 | 3 | xslF345X06/ownership.xml | 0001185185-26-003409 | 23781 | ||||||
| 2026-08-11 | 3 | xslF345X06/ownership.xml | 0001185185-26-003408 | 47433 | ||||||
| 2026-08-11 | CERT | VOGX_8A_Cert_1903784.pdf | 0001354457-26-000775 | 001-43441 | 261262520 | 34 | 654315 | |||
| 2026-08-10 | 8-A12B | FORM 8-A12B | 0001185185-26-003355 | 001-43441 | 261257482 | 34 | 27194 | |||
| 2026-08-10 | S-1/A | FORM S-1/A2 | 0001185185-26-003353 | 333-297487 | 261257464 | 33 | 4553910 | |||
| 2026-07-29 | S-1/A | FORM S-1/A | 0001185185-26-003162 | 333-297487 | 261218875 | 33 | 7442656 | 1 | 1 | |
| 2026-07-15 | S-1 | FORM S-1 | 0001185185-26-002985 | 333-297487 | 261178161 | 33 | 5451124 | 1 | 1 | |
| 2026-06-30 | DRS/A | filename1.htm | 0001185185-26-002747 | 377-09094 | 261141526 | 33 | 4296400 | |||
| 2026-04-02 | DRS/A | filename1.htm | 0001185185-26-001233 | 377-09094 | 26832914 | 33 | 3499241 | |||
| 2026-02-20 | DRS | filename1.htm | 0001185185-26-000633 | 377-09094 | 26658007 | 33 | 4286424 | |||
| 2026-01-07 | D | xslFormDX01/primary_doc.xml | 06b | 0001903784-26-000002 | 021-569148 | 26513460 | 33 | 10216 |
One latest value per concept from companyfacts (91 concepts). Full history stays in the JSON.
| Taxonomy | Tag | Label | Unit | Value | Start | End | FY | FP | Form | Filed | Accn |
|---|---|---|---|---|---|---|---|---|---|---|---|
| dei | EntityCommonStockSharesOutstanding | Entity Common Stock, Shares Outstanding | shares | 14.86M | 2026-11-05 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001185185-26-005245 | |
| ffd | NetFeeAmt | NetFeeAmt | USD | 3,222.45 | 2026-08-11 | S-8 | 2026-08-13 | 0001185185-26-003503 | |||
| ffd | TtlFeeAmt | TtlFeeAmt | USD | 3,222.45 | 2026-08-11 | S-8 | 2026-08-13 | 0001185185-26-003503 | |||
| ffd | TtlOfferingAmt | TtlOfferingAmt | USD | 23.33M | 2026-08-11 | S-8 | 2026-08-13 | 0001185185-26-003503 | |||
| ffd | TtlOffsetAmt | TtlOffsetAmt | USD | 0 | 2026-08-11 | S-8 | 2026-08-13 | 0001185185-26-003503 | |||
| ffd | TtlPrevslyPdAmt | TtlPrevslyPdAmt | USD | 10,357.5 | 2026-07-28 | S-1/A | 2026-07-29 | 0001185185-26-003162 | |||
| us-gaap | AccountsPayableCurrent | Accounts Payable, Current | USD | 523,570 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001185185-26-005245 | |
| us-gaap | AccountsPayableCurrentAndNoncurrent | Accounts Payable | USD | 1.06M | 2026-06-30 | 2026 | Q2 | 10-Q | 2026-09-17 | 0001185185-26-004101 | |
| us-gaap | AccruedBonusesCurrent | Accrued Bonuses, Current | USD | 200,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001185185-26-005245 | |
| us-gaap | AccruedBonusesCurrentAndNoncurrent | Accrued Bonuses | USD | 286,500 | 2026-06-30 | 2026 | Q2 | 10-Q | 2026-09-17 | 0001185185-26-004101 | |
| us-gaap | AccruedLiabilitiesCurrent | Accrued Liabilities, Current | USD | 318,900 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001185185-26-005245 | |
| us-gaap | AdditionalPaidInCapital | Additional Paid in Capital | USD | 98.61M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001185185-26-005245 | |
| us-gaap | AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue | APIC, Share-based Payment Arrangement, Increase for Cost Recognition | USD | 4,708 | 2026-07-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001185185-26-005245 |
| us-gaap | AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs | USD | 2.49M | 2026-07-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001185185-26-005245 |
| us-gaap | AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | shares | 561,657 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001185185-26-005245 |
| us-gaap | Assets | Assets | USD | 82.84M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001185185-26-005245 | |
| us-gaap | AssetsCurrent | Assets, Current | USD | 82.84M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001185185-26-005245 | |
| us-gaap | AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax | Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax | USD | 0 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001185185-26-005245 | |
| us-gaap | AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax | Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax | USD | 177,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001185185-26-005245 | |
| us-gaap | AvailableForSaleDebtSecuritiesAmortizedCostBasis | Debt Securities, Available-for-sale, Amortized Cost | USD | 76.99M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001185185-26-005245 | |
| us-gaap | AvailableForSaleSecuritiesDebtSecurities | Debt Securities, Available-for-sale | USD | 76.81M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001185185-26-005245 | |
| us-gaap | CashAndCashEquivalentsAtCarryingValue | Cash and Cash Equivalents, at Carrying Value | USD | 5.13M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001185185-26-005245 | |
| us-gaap | CashCashEquivalentsAndShortTermInvestments | Cash, Cash Equivalents, and Short-term Investments | USD | 82.10M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001185185-26-005245 | |
| us-gaap | CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | USD | 5.13M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001185185-26-005245 | |
| us-gaap | CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect | USD | 4.53M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001185185-26-005245 |
| us-gaap | ClassOfWarrantOrRightOutstanding | Class of Warrant or Right, Outstanding | shares | 0 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001185185-26-005245 | |
| us-gaap | CommitmentsAndContingencies | Commitments and Contingencies | USD | 0 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001185185-26-005245 | |
| us-gaap | CommonStockParOrStatedValuePerShare | Common Stock, Par or Stated Value Per Share | USD/shares | 0 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001185185-26-005245 | |
| us-gaap | CommonStockSharesAuthorized | Common Stock, Shares Authorized | shares | 500.00M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001185185-26-005245 | |
| us-gaap | CommonStockSharesIssued | Common Stock, Shares, Issued | shares | 14.86M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001185185-26-005245 | |
| us-gaap | CommonStockSharesOutstanding | Common Stock, Shares, Outstanding | shares | 14.86M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001185185-26-005245 | |
| us-gaap | CommonStockValue | Common Stock, Value, Issued | USD | 1,485 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001185185-26-005245 | |
| us-gaap | ConvertibleDebtFairValueDisclosures | Convertible Debt, Fair Value Disclosures | USD | 894,477 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001185185-26-005245 | |
| us-gaap | ConvertibleNotesPayableCurrent | Convertible Notes Payable, Current | USD | 0 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001185185-26-005245 | |
| us-gaap | ConvertiblePreferredStockSharesReservedForFutureIssuance | Convertible Preferred Stock, Shares Reserved for Future Issuance | shares | 0 | 2026-08-31 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001185185-26-005245 | |
| us-gaap | DebtConversionConvertedInstrumentAmount1 | Debt Conversion, Converted Instrument, Amount | USD | 833,326 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001185185-26-005245 |
| us-gaap | DebtConversionConvertedInstrumentRate | Debt Conversion, Converted Instrument, Rate | pure | 0.9 | 2025-12-08 | 2026 | Q2 | 10-Q | 2026-09-17 | 0001185185-26-004101 | |
| us-gaap | DebtInstrumentFaceAmount | Debt Instrument, Face Amount | USD | 750,000 | 2025-12-08 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001185185-26-005245 | |
| us-gaap | DebtInstrumentInterestRateIncreaseDecrease | Debt Instrument, Interest Rate, Increase (Decrease) | pure | 0.18 | 2025-12-08 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001185185-26-005245 | |
| us-gaap | DebtInstrumentInterestRateStatedPercentage | Debt Instrument, Interest Rate, Stated Percentage | pure | 0.12 | 2025-12-08 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001185185-26-005245 | |
| us-gaap | DeferredCompensationArrangementWithIndividualCashAwardGrantedAmount | Deferred Compensation Arrangement with Individual, Cash Award Granted, Amount | USD | 719,043 | 2026-06-30 | 2026 | Q2 | 10-Q | 2026-09-17 | 0001185185-26-004101 | |
| us-gaap | DeferredOfferingCosts | Deferred Offering Costs | USD | 0 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001185185-26-005245 | |
| us-gaap | DerivativeLiabilitiesCurrent | Derivative Liability, Current | USD | 0 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001185185-26-005245 | |
| us-gaap | DerivativeLiabilitiesNoncurrent | Derivative Liability, Noncurrent | USD | 3.40M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001185185-26-005245 | |
| us-gaap | EarningsPerShareBasic | Earnings Per Share, Basic | USD/shares | -0.82 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001185185-26-005245 |
| us-gaap | EarningsPerShareDiluted | Earnings Per Share, Diluted | USD/shares | -0.82 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001185185-26-005245 |
| us-gaap | FairValueAdjustmentOfWarrants | Fair Value Adjustment of Warrants | USD | 3.43M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001185185-26-005245 |
| us-gaap | GainLossOnInvestments | Gain (Loss) on Investments | USD | 27,000 | 2026-07-01 | 2026-08-31 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001185185-26-005245 |
| us-gaap | GeneralAndAdministrativeExpense | General and Administrative Expense | USD | 1.13M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001185185-26-005245 |
| us-gaap | IncreaseDecreaseInAccountsPayable | Increase (Decrease) in Accounts Payable | USD | 505,842 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001185185-26-005245 |
| us-gaap | IncreaseDecreaseInAccruedLiabilities | Increase (Decrease) in Accrued Liabilities | USD | -390,918 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001185185-26-005245 |
| us-gaap | IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets | Increase (Decrease) in Prepaid Expense and Other Assets | USD | 482,717 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001185185-26-005245 |
| us-gaap | InterestPaidNet | Interest Paid, Excluding Capitalized Interest, Operating Activities | USD | 61,151 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001185185-26-005245 |
| us-gaap | InterestPayableCurrentAndNoncurrent | Interest Payable | USD | 61,151 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001185185-26-005245 | |
| us-gaap | InterestReceivable | Interest Receivable | USD | 270,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001185185-26-005245 | |
| us-gaap | InvestmentIncomeInterest | Investment Income, Interest | USD | 338,726 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001185185-26-005245 |
| us-gaap | Liabilities | Liabilities | USD | 842,470 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001185185-26-005245 | |
| us-gaap | LiabilitiesAndStockholdersEquity | Liabilities and Equity | USD | 82.84M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001185185-26-005245 | |
| us-gaap | LiabilitiesCurrent | Liabilities, Current | USD | 842,470 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001185185-26-005245 | |
| us-gaap | MarketableSecuritiesCurrent | Marketable Securities, Current | USD | 76.99M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001185185-26-005245 | |
| us-gaap | NetCashProvidedByUsedInFinancingActivities | Net Cash Provided by (Used in) Financing Activities | USD | 84.43M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001185185-26-005245 |
| us-gaap | NetCashProvidedByUsedInInvestingActivities | Net Cash Provided by (Used in) Investing Activities | USD | -76.99M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001185185-26-005245 |
| us-gaap | NetCashProvidedByUsedInOperatingActivities | Net Cash Provided by (Used in) Operating Activities | USD | -2.92M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001185185-26-005245 |
| us-gaap | NetIncomeLoss | Net Income (Loss) Attributable to Parent | USD | -5.77M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001185185-26-005245 |
| us-gaap | NoninterestExpenseDirectorsFees | Noninterest Expense Directors Fees | USD | 90,000 | 2026-01-01 | 2026-06-30 | 2026 | Q2 | 10-Q | 2026-09-17 | 0001185185-26-004101 |
| us-gaap | NonoperatingIncomeExpense | Nonoperating Income (Expense) | USD | -3.17M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001185185-26-005245 |
| us-gaap | NumberOfReportableSegments | Number of Reportable Segments | segment | 1 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001185185-26-005245 |
| us-gaap | OperatingExpenses | Operating Expenses | USD | 2.60M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001185185-26-005245 |
| us-gaap | OtherNonoperatingIncomeExpense | Other Nonoperating Income (Expense) | USD | -3.17M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001185185-26-005245 |
| us-gaap | OtherResearchAndDevelopmentExpense | Other Research and Development Expense | USD | 21,945 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001185185-26-005245 |
| us-gaap | PaymentOfFinancingAndStockIssuanceCosts | Payment of Financing and Stock Issuance Costs | USD | 2.47M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001185185-26-005245 |
| us-gaap | PaymentsOfStockIssuanceCosts | Payments of Stock Issuance Costs | USD | 84,874 | 2026-01-01 | 2026-06-30 | 2026 | Q2 | 10-Q | 2026-09-17 | 0001185185-26-004101 |
| us-gaap | PaymentsToAcquireMarketableSecurities | Payments to Acquire Marketable Securities | USD | 76.99M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001185185-26-005245 |
| us-gaap | PreferredStockParOrStatedValuePerShare | Preferred Stock, Par or Stated Value Per Share | USD/shares | 0 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001185185-26-005245 | |
| us-gaap | PreferredStockSharesAuthorized | Preferred Stock, Shares Authorized | shares | 10.00M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001185185-26-005245 | |
| us-gaap | PreferredStockSharesIssued | Preferred Stock, Shares Issued | shares | 0 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001185185-26-005245 | |
| us-gaap | PreferredStockSharesOutstanding | Preferred Stock, Shares Outstanding | shares | 0 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001185185-26-005245 | |
| us-gaap | PreferredStockValue | Preferred Stock, Value, Issued | USD | 0 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001185185-26-005245 | |
| us-gaap | PrepaidExpenseAndOtherAssetsCurrent | Prepaid Expense and Other Assets, Current | USD | 725,193 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001185185-26-005245 | |
| us-gaap | PrepaidInsurance | Prepaid Insurance | USD | 523,000 | 2026-08-31 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001185185-26-005245 | |
| us-gaap | ProceedsFromIssuanceOfCommonStock | Proceeds from Issuance of Common Stock | USD | 86.90M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001185185-26-005245 |
| us-gaap | ResearchAndDevelopmentExpense | Research and Development Expense | USD | 1.47M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001185185-26-005245 |
| us-gaap | RetainedEarningsAccumulatedDeficit | Retained Earnings (Accumulated Deficit) | USD | -16.61M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001185185-26-005245 | |
| us-gaap | ShareBasedCompensation | Share-based Payment Arrangement, Noncash Expense | USD | 4,524 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001185185-26-005245 |
| us-gaap | SharePrice | Share Price | USD/shares | 13 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001185185-26-005245 | |
| us-gaap | StockholdersEquity | Stockholders' Equity Attributable to Parent | USD | 82.00M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001185185-26-005245 | |
| us-gaap | StockIssuedDuringPeriodSharesOther | Stock Issued During Period, Shares, Other | shares | 7.00M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001185185-26-005245 |
| us-gaap | StockIssuedDuringPeriodValueNewIssues | Stock Issued During Period, Value, New Issues | USD | 86.90M | 2026-07-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001185185-26-005245 |
| us-gaap | StockIssuedDuringPeriodValueOther | Stock Issued During Period, Value, Other | USD | 833,326 | 2026-07-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001185185-26-005245 |
| us-gaap | WeightedAverageNumberOfDilutedSharesOutstanding | Weighted Average Number of Shares Outstanding, Diluted | shares | 7.00M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001185185-26-005245 |
| us-gaap | WeightedAverageNumberOfSharesOutstandingBasic | Weighted Average Number of Shares Outstanding, Basic | shares | 7.00M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001185185-26-005245 |